Table 2

Association between baseline autoantibody status and radiological destruction

RF+ (n = 162) vs RF- (n = 94)

Anti-CCP + (n = 148) vs anti-CCP- (n = 108)

Anti-MCV+ (n = 180) vs anti-MCV- (n = 74)

Anti-CII + (> 200 AU/mL; n = 8) versus anti-CII- (n = 248)

Larsen score baseline

4.000 versus 5.000, P = NS (0.13)

4.000 versus 5.000, P = NS (0.16)

4.375 versus 5.000, P = NS (0.21)

13.750 versus 4.375, P = 0.0486*

Larsen score 1 year

10,500 versus10.500, P = NS (0.65)

10.500 versus 10,750, P = NS (0.66)

11.000 versus 10.000, P = NS (0.99)

21.500 versus 10.500, P = NS (0.0799)

Larsen score 2 years

14.000 versus 13.250, P = NS (0.69)

14.000 versus 13.000, P = NS (0.57)

14.375 versus 10,250, P = NS (0.24)

24.000 versus 13.500, P = NS (0.19)

ΔLarsen score 1 yr -baseline

4.500 versus 4.250, P = NS (0.32)

4.500 versus 4.250, P = NS (0.29)

4.500 versus 3.750, P = NS (0.19)

7.375 versus 4.250, P = NS (0.27)

ΔLarsen score 2 yrs -baseline

7.250 versus 6.250, P = 0.0354*

7.500 versus 6.250

P = 0.0102*

7.750 versus 5.250, P = 0.0028*

9.250 versus 6.500, P = NS (0.50)

ΔLarsen score 2 yrs -1 yr

2.500 versus 1.250, P = 0.0009*

2.750 versus 1.000, p < 0.0001*

2.750 versus 1.000, p < 0.0001*

3.000 versus 2,.250, P = NS (0.48)

Differences in median Larsen score between patients with and without different autoantibodies and changes in median Larsen score are given for 256 patients with early rheumatoid arthritis. Anti-MCV data were missing for two patients. ΔLarsen score, difference in Larsen score; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide antibodies; Anti-MCV, antibodies against modified citrullinated vimentin; Anti-CII, anti-native human collagen type II. *P < 0.05.

Mullazehi et al. Arthritis Research & Therapy 2012 14:R100   doi:10.1186/ar3825